KEGG   DRUG: Lirilumab
Entry
D10444                      Drug                                   
Name
Lirilumab (USAN/INN)
Formula
C6452H9918N1698O2030S46
Exact mass
145137.2203
Mol weight
145227.01
Sequence
(Heavy chain)
QVQLVQSGAE VKKPGSSVKV SCKASGGTFS FYAISWVRQA PGQGLEWMGG FIPIFGAANY
AQKFQGRVTI TADESTSTAY MELSSLRSDD TAVYYCARIP SGSYYYDYDM DVWGQGTTVT
VSSASTKGPS VFPLAPCSRS TSESTAALGC LVKDYFPEPV TVSWNSGALT SGVHTFPAVL
QSSGLYSLSS VVTVPSSSLG TKTYTCNVDH KPSNTKVDKR VESKYGPPCP PCPAPEFLGG
PSVFLFPPKP KDTLMISRTP EVTCVVVDVS QEDPEVQFNW YVDGVEVHNA KTKPREEQFN
STYRVVSVLT VLHQDWLNGK EYKCKVSNKG LPSSIEKTIS KAKGQPREPQ VYTLPPSQEE
MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SRLTVDKSRW
QEGNVFSCSV MHEALHNHYT QKSLSLSLG
(Light chain)
EIVLTQSPVT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD ASNRATGIPA
RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWMYTFGQ GTKLEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H96, H137-L214, H150-H206, H229-H'229, H232-H'232, H264-H324, H370-H428, H'22-H'96, H'137-L'214, H'150-H'206, H'264-H'324, H'370-H'428, L23-L88, L134-L194, L'23-L'88, L'134-L'194; Modified residue: H1', H1' Q=pyroglutamic acid [CPD:C01879]; Glycosylation site: H300, H'300)
  Type
Peptide
Efficacy
Antineoplastic, Anti-KIR antibody
  Type
Monoclonal antibody
Comment
Solid and hematological cancers
Target
KIR2DL (CD158) [HSA:3802 3803 3804] [KO:K07981]
Brite
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   CD molecules
    KIR2DL (CD158)
     D10444  Lirilumab (USAN/INN)
Other DBs
CAS: 1000676-41-4
PubChem: 172232537
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system